OMEROS CORP Debt Instrument, Unamortized Discount (Premium), Net
OMEROS CORP (OMER) had Debt Instrument, Unamortized Discount (Premium), Net of $6.51 million as of 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net › Debt Instrument, Unamortized Discount (Premium), Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet · last filed 2018-11-08
- 2018-09-30: Debt Instrument, Unamortized Discount (Premium), Net $6.51M.
- 2018-06-30: Debt Instrument, Unamortized Discount (Premium), Net $6.83M.
- 2018-03-31: Debt Instrument, Unamortized Discount (Premium), Net $3.40M.
- 2017-12-31: Debt Instrument, Unamortized Discount (Premium), Net $3.53M.
| Period end | Debt Instrument, Unamortized Discount (Premium), Net |
|---|---|
| 2018-09-30 | $6.51M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $6.83M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $3.40M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $3.53M 10-Q · filed 2018-11-08 |
| 2017-09-30 | $3.64M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $3.75M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $3.86M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $3.96M 10-K · filed 2018-03-01 |
| 2015-12-31 | $3.75M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |